📢 Exciting News! We successfully raised 6.5M euros in Round C financing! Thanks to our shareholders for their confidence in #OncoDNA's vision. Our objective: double-digit, profitable growth in #personalizedmedicine. Introducing the #OncoDEEPKit, empowering tailored solutions!
🚀 Introducing our new lab solutions portal! 🧬🔬 Access cutting-edge scientific info, research papers, clinical trials, and more in oncology, genetics, and precision medicine. 🔗 https://t.co/ZOokKGMobh #labsolutions#oncology#genetics#precisionmedicine#innovation
We are thrilled to unveil the exceptional quality of the OncoDEEP Kit's HRD assessment presented in our new article "Homologous Recombination Deficiency (#HRD) assessment for clinical management using the OncoDEEP Kit" => https://t.co/ZKLIW0YC5A 💥
#labs#precisionmedicine
#OncoDNA se enorgullece de haber sido seleccionada en la Fase 1 del Procedimiento de Adquisición Pre-comercial de oncNGS con el objetivo de desarrollar una solución para el análisis por NGS de biopsias líquidas de pacientes oncológicos🧬
#oncodna#oncologiadeprecisión
Our merry team at @OncoDNA is sending their very best wishes for this holiday season🎄and wishing you a sparkling New Year🎉. We are grateful for the trust you have placed in us, and we hope to keep on bringing you closer to your dreams in the year to come✨.
We are delighted to communicate about our collaboration with @LillyPad - Italia to broaden access to biomarker testing for #thyroid cancer patients 🧬.
Discover all details in our press release: https://t.co/oh0Avki5DJ
#oncodna#oncodeep#cancer#precisiononcology#NGS
OncoDNA is pleased to announce a transformational partnership with the Berkshire and Surrey Pathology Services to facilitate Private NGS testing across UK 🙌.
Discover all details in our press release: https://t.co/ypovd0cyTm
#oncodna#oncodeep#precisiononcology
We have launched our new #OncoDEEP Kit during the #ESMO in Paris. It enables laboratories with #NGS capabilities to support oncologists in finding the most effective and personalized treatments for their cancer patients🔬.
Discover all details: https://t.co/f5BoRrVGrD
ALK. ROS1. FGFR. NTRK. BRAF. They are all #genefusion biomarkers that can predict a patient’s sensitivity to targeted and hormone therapy. Watch the video to understand how to detect them in patients.
https://t.co/zGpOEp7mon
#oncology#OncoDEEP#precisionmedicine
Why test patients with metastatic castration-resistant #prostatecancer for #ARV7?
This #biomarker is associated with a poor prognostic indicator for the efficacy of #hormonetherapies such as abiraterone or enzalutamide.
#OncoDEEP can help detect it =>
https://t.co/ocmkWnzmIA